Anzeige
Mehr »
Login
Dienstag, 07.12.2021 Börsentäglich über 12.000 News von 681 internationalen Medien
Wachgeküsst! Vom „Diesel-Entlein“ zum „Elektro-Schwan“!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AG0F ISIN: SE0006091997 Ticker-Symbol: 1YR 
Frankfurt
07.12.21
08:02 Uhr
7,485 Euro
-0,140
-1,84 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMMUNOVIA AB Chart 1 Jahr
5-Tage-Chart
IMMUNOVIA AB 5-Tage-Chart
PR Newswire
262 Leser
Artikel bewerten:
(1)

Immunovia AB: Immunovia appoints new Senior Director Investor Relations and Corporate Communications

LUND, Sweden, Nov. 26, 2021 /PRNewswire/ -- Immunovia AB (publ) announces that Tobias Bülow has been appointed new Senior Director Investor Relations and Corporate Communications, taking up his position January 15. Tobias has s solid IR and Corporate Communications background with extensive experience from international high-tech companies.

Tobias joins Immunovia from Mycronic AB (publ), where he most recently held the position of Director Investor Relations. Previous experiences include Director Financial Communications at the radiation therapy company Elekta AB (publ).

"I am very pleased to welcome Tobias to Immunovia and the role as Senior Director Investor Relations and Corporate Communications. Tobias has a solid international background from leading positions and companies. I am convinced he has the drive, skills, and experience to contribute in shaping Immunovia's continued journey," says Patrik Dahlen, CEO of Immunovia.

For more information, please contact:
Patrik Dahlen, CEO Immunovia
Email: patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64

About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia's proprietary test platform called IMMray. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".

The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.

The first product, IMMray PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.

In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/immunovia-ab/r/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications,c3461283

The following files are available for download:

https://mb.cision.com/Main/13121/3461283/1502042.pdf

Press release (PDF)

IMMUNOVIA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.